236 related articles for article (PubMed ID: 33334316)
41. Effect of brimonidine on intraocular pressure in normal tension glaucoma: a short term clinical trial.
Gandolfi SA; Cimino L; Mora P
Eur J Ophthalmol; 2003; 13(7):611-5. PubMed ID: 14552594
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
Simmons ST;
Clin Ther; 2001 Apr; 23(4):604-19. PubMed ID: 11354394
[TBL] [Abstract][Full Text] [Related]
43. Comparison of different combinations of maximum medical therapy for lowering intraocular pressure in primary open angle glaucoma: 12-month retrospective consecutive case series.
Joh HJ; Jin SW
Jpn J Ophthalmol; 2019 Jul; 63(4):322-327. PubMed ID: 31115761
[TBL] [Abstract][Full Text] [Related]
44. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States.
Camras CB; Sheu WP;
J Glaucoma; 2005 Apr; 14(2):161-7. PubMed ID: 15741820
[TBL] [Abstract][Full Text] [Related]
45. Effects of Switching from Timolol to Brimonidine in Prostaglandin Analog and Timolol Combination Therapy.
Aihara M; Adachi M; Hamada N; Honda N; Koseki N; Matsuo H; Miyata K; Otani S; Unoki K
J Ocul Pharmacol Ther; 2015 Oct; 31(8):482-6. PubMed ID: 26114331
[TBL] [Abstract][Full Text] [Related]
46. [Anterior uveitis and topical brimonidine: a case report].
Velasque L; Ducousso F; Pernod L; Vignal R; Deral V
J Fr Ophtalmol; 2004 Dec; 27(10):1150-2. PubMed ID: 15687926
[TBL] [Abstract][Full Text] [Related]
47. Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial.
Fechtner RD; Myers JS; Hubatsch DA; Budenz DL; DuBiner HB
Eye (Lond); 2016 Oct; 30(10):1343-1350. PubMed ID: 27367743
[TBL] [Abstract][Full Text] [Related]
48. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate.
Becker HI; Walton RC; Diamant JI; Zegans ME
Arch Ophthalmol; 2004 Jul; 122(7):1063-6. PubMed ID: 15249377
[No Abstract] [Full Text] [Related]
49. Brimonidine-induced anterior uveitis and conjunctivitis: clinical and histologic features.
Nguyen EV; Azar D; Papalkar D; McCluskey P
J Glaucoma; 2008; 17(1):40-2. PubMed ID: 18303383
[TBL] [Abstract][Full Text] [Related]
50. Bimatoprost 0.03% versus brimonidine 0.2% in the prevention of intraocular pressure spike following neodymium:yttrium–aluminum–garnet laser posterior capsulotomy.
Artunay O; Yuzbasioglu E; Unal M; Rasier R; Sengul A; Bahcecioglu H
J Ocul Pharmacol Ther; 2010 Oct; 26(5):513-7. PubMed ID: 20874499
[TBL] [Abstract][Full Text] [Related]
51. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
Katz LJ
Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
[TBL] [Abstract][Full Text] [Related]
52. Ocular complications of latanoprost in uveitic glaucoma: three case reports.
Saccà S; Pascotto A; Siniscalchi C; Rolando M
J Ocul Pharmacol Ther; 2001 Apr; 17(2):107-13. PubMed ID: 11324978
[TBL] [Abstract][Full Text] [Related]
53. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
Serle JB
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
[TBL] [Abstract][Full Text] [Related]
54. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
55. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial.
Cantor LB; Safyan E; Liu CC; Batoosingh AL
Curr Med Res Opin; 2008 Jul; 24(7):2035-43. PubMed ID: 18534052
[TBL] [Abstract][Full Text] [Related]
56. Brimonidine tartrate: a one-month dose response study.
Derick RJ; Robin AL; Walters TR; Barnebey HS; Choplin N; Schuman J; Kelley EP; Chen K; Stoecker JF
Ophthalmology; 1997 Jan; 104(1):131-6. PubMed ID: 9022117
[TBL] [Abstract][Full Text] [Related]
57. Brinzolamide/brimonidine: a review of its use in patients with open-angle glaucoma or ocular hypertension.
Greig SL; Deeks ED
Drugs Aging; 2015 Mar; 32(3):251-60. PubMed ID: 25732405
[TBL] [Abstract][Full Text] [Related]
58. The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%.
Stewart WC; Stewart JA; Day DG; Jenkins J
Acta Ophthalmol Scand; 2004 Apr; 82(2):161-5. PubMed ID: 15043534
[TBL] [Abstract][Full Text] [Related]
59. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
60. Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye.
Carrasco MA; Schlaen BA; Zárate JO
Int Ophthalmol; 2013 Oct; 33(5):557-60. PubMed ID: 23224363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
